Abstract
INTRODUCTION:Metachromatic leukodystrophy (MLD) is an infrequent disease characterized by progressive demyelination of the central and peripheral nervous system. In most cases, it is caused by deficient activity of arylsulfatase-A. It belongs to the group of leukodystrophies, which are inherited white matter disorders that can be associated with significant phenotypic variability and genetic heterogeneity. The phenotype in MLD is usually related to the age of onset, which can vary from childhood to adulthood. Adult-onset MLD can debut with neuropsychiatry symptoms, which can often lead to misdiagnosis.
CASE REPORT:We report the case of an adult female patient who presented with progressive behavioral changes, followed by motor manifestations. MLD was initially suspected based on the clinical presentation and the characteristic findings on brain magnetic resonance imaging (MRI), with subsequent confirmation by detection of deficient arylsulfatase-A (ARSA) activity and ARSA gene sequencing, which demonstrated homozygosity, compatible with this diagnosis.
DISCUSSION:We highlight the importance of clinical suspicion, early recognition and multidisciplinary management as a prognostic factor for the course of the disease, since there is currently no definitive treatment for the disease.
References
Köhler W Curiel J, Vanderver A. Adulthood leukodystrophies. Nat Rev Neurol. 2018;14(2):94-105.
Gomez-Ospina N. Arylsulfatase a deficiency. En: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Mirzaa G, et al., editores. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [consultado 27 Abr. 2021]. Disponible en: Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK1130/
Polten A, Fluharty AL, Fluharty CB, Kappler J, von Figura K, Gieselmann V. Molecular basis of different forms of meta-chromatic leukodystrophy. N Engl J Med. 1991;324(1):18-22.
Espejo LM, de la Espriella R, Hernández JF. Leucodistrofia metacromática. Presentación de caso. Rev Colomb Psiquiatr. 2017;46(1):44-9.
Harrington M, Whalley D, Twiss J, Rushton R, Martin S, Huynh L, et al. Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers. Orphanet J Rare Dis. 2019;14(1):89.
Kehrer C, Elgün S, Raabe C, Bóhringer J, Beck-Wódl S, Bevot A, et al. Association of age at onset and first symptoms with disease progression in patients with metachromatic leukodys-trophy. Neurology. 2021;96(2):e255-66.
Gieselmann V. Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic options. Acta Paediatr Oslo Nor 1992. 2008;97(457):15-21.
Shaimardanova AA, Chulpanova DS, Solovyeva VV, Mullagu-lova AI, Kitaeva KV, Allegrucci C, et al. Metachromatic leukodystrophy: diagnosis, modeling, and treatment approaches. Front Med [Internet]. 2020 [consultado 27 Abr. 2021];7. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606900/
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.